Laboratorios Farmaceuticos Rovi (STU:41L) 3-Year EPS without NRI Growth Rate : 40.40% (As of Jun. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Laboratorios Farmaceuticos Rovi 3-Year EPS without NRI Growth Rate?

Laboratorios Farmaceuticos Rovi's EPS without NRI for the three months ended in Jun. 2024 was €0.57.

During the past 12 months, Laboratorios Farmaceuticos Rovi's average EPS without NRI Growth Rate was -19.70% per year. During the past 3 years, the average EPS without NRI Growth Rate was 40.40% per year. During the past 5 years, the average EPS without NRI Growth Rate was 61.90% per year. During the past 10 years, the average EPS without NRI Growth Rate was 26.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Laboratorios Farmaceuticos Rovi was 98.30% per year. The lowest was -10.40% per year. And the median was 10.40% per year.

Competitive Comparison of Laboratorios Farmaceuticos Rovi's 3-Year EPS without NRI Growth Rate

For the Biotechnology subindustry, Laboratorios Farmaceuticos Rovi's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Laboratorios Farmaceuticos Rovi's 3-Year EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Laboratorios Farmaceuticos Rovi's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Laboratorios Farmaceuticos Rovi's 3-Year EPS without NRI Growth Rate falls into.

Laboratorios Farmaceuticos Rovi 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

Laboratorios Farmaceuticos Rovi (STU:41L) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.

Laboratorios Farmaceuticos Rovi 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Laboratorios Farmaceuticos Rovi's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Laboratorios Farmaceuticos Rovi Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Laboratorios Farmaceuticos Rovi SA (STU:41L) » Definitions » 3-Year EPS without NRI Growth Rate

Comparable Companies

Traded in Other Exchanges

ROVI:Mexico ROVIe:UK 0ILL:UK ROVI:Spain

Address

Julian Camarillo, 35, Madrid, ESP, 28037

Website

https://www.rovi.es

Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.

Laboratorios Farmaceuticos Rovi Headlines

No Headlines